Jefremow A, Wiesmüller M, Rouse RA, Dietrich P, Kremer A, Waldner M, Neurath M, Siebler J (2020)
Publication Type: Journal article
Publication year: 2020
Book Volume: 71
Pages Range: 717-728
Journal Issue: 5
The systemic treatment of unresectable hepatocellular carcinoma (HCC) has been improved throughout the past years. Different tyrosine kinase inhibitors (TKI) and checkpoint inhibitors have approval for first-and second-line treatment. Still, data are missing about the choice for the right agent and senseful therapy sequences. Between 2017 and 2019 we treated 149 HCC patients. From those, we identified the patients, who received lenvatinib either as a first-line treatment or in a later treatment line. We investigated seven patients retrospectively, who received lenvatinib in second, third, or fourth treatment line regarding efficacy and safety. Besides that, we compared those patients with 13 patients, who received lenvatinib as a first-line treatment regarding duration of therapy, overall survivial (OS), side effects and best response to treatment. We discovered remission (PR) showed 4/7, stable disease (SD) 2/7 and 1/7 mixed response with an overall tolerable safety profile in patients with a later line lenvatinib treatment. The duration and overall survival for therapy is similar in first-and later treatment lines with comparable results. Most side effects are moderate in each treatment line. Remarkably, on patient diagnoses with HCC (the Barcelona Clinic Liver Cancer C algorithm), who received lenvatinib in fourth line reached 67 months OD since diagnosis. We conclude, that lenvatinib could be considered as a treatment option of HCC for later treatment lines.
APA:
Jefremow, A., Wiesmüller, M., Rouse, R.A., Dietrich, P., Kremer, A., Waldner, M.,... Siebler, J. (2020). Beyond the border: The use of lenvatinib in advanced hepatocellular carcinoma after different treatment lines: A retrospective analysis. Journal of Physiology and Pharmacology, 71(5), 717-728. https://doi.org/10.26402/jpp.2020.5.11
MLA:
Jefremow, Andre, et al. "Beyond the border: The use of lenvatinib in advanced hepatocellular carcinoma after different treatment lines: A retrospective analysis." Journal of Physiology and Pharmacology 71.5 (2020): 717-728.
BibTeX: Download